New hope for heart health in kidney transplant patients?
NCT ID NCT04608474
First seen Apr 17, 2026 · Last updated May 24, 2026 · Updated 6 times
Summary
This study tested a drug called evolocumab (Repatha) to lower cholesterol in 81 kidney transplant recipients. High cholesterol is common after transplant and raises heart disease risk, but standard statin drugs can cause side effects in these patients. The goal was to see if evolocumab is safe and effective for managing cholesterol in this group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERLIPIDEMIAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.